T2D patients exhibit improperly differentiated T lymphocytes [35]
And, so far, while quality and safety inspections and enforcement typical among compounders are occurring with compounders of GLP-1 products, we have not seen evidence publicly that the FDA is taking action specifically against the practice of compounding GLP-1 products that are no longer in shortage as products that are essentially a copy of the FDA-approved products
Pfizer discontinued danuglipron development due to significant tolerability issues, primarily gastrointestinal side effects such as nausea, vomiting, and diarrhoea that led to high discontinuation rates
Always consult with your healthcare provider if you have any specific concerns
It is well tolerated, easy for patients to self-administer, and it keeps mitochondrial support steady through the period when the body is doing the most cellular work
The metabolic effects on GLP-1 and insulin response of decaffeinated GTE in humans warrant continued investigation